Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement
Mohammed Eslam, Naim Alkhouri, Pietro Vajro, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 10, pp. 864-873
Closed Access | Times Cited: 202
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri, Robert Herring, Heidi Kabler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 607-618
Open Access | Times Cited: 140
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
Agnieszka Karkucińska‐Więckowska, Inês C. M. Simões, Piotr Kalinowski, et al.
European Journal of Clinical Investigation (2021) Vol. 52, Iss. 3
Open Access | Times Cited: 102
The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
Rodrigo Zamignan Carpi, Sandra Maria Barbalho, Kátia Portero Sloan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8805-8805
Open Access | Times Cited: 87
The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
Qian Song, Xiang Zhang
Biomedicines (2022) Vol. 10, Iss. 3, pp. 524-524
Open Access | Times Cited: 80
Global burden of metabolic diseases, 1990–2021
Huai Zhang, Xiaodong Zhou, Michael D. Shapiro, et al.
Metabolism (2024) Vol. 160, pp. 155999-155999
Closed Access | Times Cited: 56
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?
Mariana M. Ramírez-Mejía, Carlos Jiménez-Gutiérrez, Mohammed Eslam, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 168-178
Closed Access | Times Cited: 50
The Link between NAFLD and Metabolic Syndrome
Fabiana Radu, Claudia-Gabriela Potcovaru, Teodor Salmen, et al.
Diagnostics (2023) Vol. 13, Iss. 4, pp. 614-614
Open Access | Times Cited: 43
Association Between Non-alcoholic Fatty Liver Disease and Heavy Metal Exposure: a Systematic Review
Parisa Sadighara, Amir Hossein Abedini, Namra Irshad, et al.
Biological Trace Element Research (2023) Vol. 201, Iss. 12, pp. 5607-5615
Closed Access | Times Cited: 41
TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase
Suowen Xu, Xiumei Wu, Sichen Wang, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 5
Open Access | Times Cited: 15
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
О. М. Драпкина, А. V. Kontsevaya, А. М. Калинина, et al.
CARDIOVASCULAR THERAPY AND PREVENTION (2024) Vol. 23, Iss. 3, pp. 3696-3696
Open Access | Times Cited: 14
Association between NAFLD and liver fibrosis with nutritional risk index based on the NHANES 2017–2018
Jie-Ming Jian, Rui Zhang, Yuan Dong, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study
Laurens A. van Kleef, Ibrahim Ayada, Louise J. M. Alferink, et al.
Hepatology (2021) Vol. 75, Iss. 2, pp. 419-429
Open Access | Times Cited: 77
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
Christopher D. Byrne, Giovanni Targher
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S2, pp. 28-43
Open Access | Times Cited: 75
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Marco Arrese, Juan Pablo Arab, Francisco Barrera, et al.
Seminars in Liver Disease (2021) Vol. 41, Iss. 04, pp. 421-434
Open Access | Times Cited: 75
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications
Maria Jiménez Ramos, Lucia Bandiera, Filippo Menolascina, et al.
iScience (2021) Vol. 25, Iss. 1, pp. 103549-103549
Open Access | Times Cited: 73
CD4+ T cell activation and inflammation in NASH-related fibrosis
Yunfeng Zhou, Haibo Zhang, Yao Yao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 62
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
Marija Branković, Igor Jovanović, Marija Dukić, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5146-5146
Open Access | Times Cited: 40
SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors
Qin Sun, Xiaorui Xing, Huanyu Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115586-115586
Open Access | Times Cited: 37
From Single- to Multi-organ-on-a-Chip System for Studying Metabolic Diseases
Minjeong Jang, Hong Nam Kim
BioChip Journal (2023) Vol. 17, Iss. 2, pp. 133-146
Closed Access | Times Cited: 24
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeong Jun Song
Nutrients (2023) Vol. 15, Iss. 18, pp. 3970-3970
Open Access | Times Cited: 22
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Amedeo Lonardo, Stefano Ballestri, Alessandro Mantovani, et al.
Metabolites (2024) Vol. 14, Iss. 1, pp. 40-40
Open Access | Times Cited: 12
Prognostic nutritional index (PNI) and risk of non-alcoholic fatty liver disease and advanced liver fibrosis in US adults: Evidence from NHANES 2017–2020
Ge Chen, Liqing Fan, Ting Yang, et al.
Heliyon (2024) Vol. 10, Iss. 4, pp. e25660-e25660
Open Access | Times Cited: 10
The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis
Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2001-2016
Closed Access | Times Cited: 10
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
Jialan Wang, Suwen Jiang, Airong Hu, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27325-e27325
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top